HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons

Bibliographic Details
Main Authors:	Bihl, Florian, Martinetti, Gladys, Wandeler, Gilles, Weber, Rainer, Ledergeber, Bruno, Calmy, Alexandra, Battegay, Manuel, Cavassini, Matthias, Vernazza, Pietro, Caminada, Anna-Paola, Rickenbach, Martin, Bernasconi, Enos
Format:	Online
Language:	English
Published:	BioMed Central 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495698/

Similar Items

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
by: Cui, Guangying, et al.
Published: (2015)

Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis
by: Price, Huw, et al.
Published: (2013)

Stress Studies of Tenofovir Disoproxil Fumarate by HPTLC in Bulk Drug and Pharmaceutical Formulation
by: Havele, Shweta, et al.
Published: (2012)

Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?
by: Kim, Ji Hoon, et al.
Published: (2015)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
by: Wang, Huilian, et al.
Published: (2016)

Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection
by: Huang, Yu-Shan, et al.
Published: (2016)

Chances for cure in chronic HBV/HDV coinfection
by: Iliescu, Gabriela, et al.
Published: (2014)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
by: Aoran Luo, et al.
Published: (2018-09-01)

Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial
by: Peterson, Leigh, et al.
Published: (2007)

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors
by: Pontrelli, Giuseppe, et al.
Published: (2012)

The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
by: Cassetti, I, et al.
Published: (2010)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
by: Lazzarin, A, et al.
Published: (2010)

RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
by: Bhavsar, Dhara S., et al.
Published: (2012)

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine
by: Funderburg, Nicholas T., et al.
Published: (2013)

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
by: Gordon, Stuart C, et al.
Published: (2013)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
by: Solomon, Marc M., et al.
Published: (2014)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Settings
by: Pan, Calvin Q., et al.
Published: (2014)

Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney
by: Abraham, Premila, et al.
Published: (2013)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Setting
Published: (2014)

Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
by: Ping Zhang, et al.
Published: (2018-08-01)

Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B
by: Lou, Lillian
Published: (2013)

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
by: Marcellin, Patrick, et al.
Published: (2016)

Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures
by: Srinivasan, Priya, et al.
Published: (2016)

Simultaneous Spectrophotometric Method for Determination of Emtricitabine and Tenofovir Disoproxil Fumarate in Three-Component Tablet Formulation Containing Rilpivirine Hydrochloride
by: Venkatesan, S., et al.
Published: (2014)

Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis
by: Valin, Nadia, et al.
Published: (2016)

Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports
by: Fox, Julie, et al.
Published: (2016)

Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya
by: Pintye, Jillian, et al.
Published: (2015)

Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?
by: Marcelin, Jasmine R., et al.
Published: (2016)

Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
by: Kojima, Noah, et al.
Published: (2016)

Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B
by: Bakhshizadeh, Fatemeh, et al.
Published: (2015)

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
by: Buti, Maria, et al.
Published: (2014)

The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort
by: Monteiro, Nadine, et al.
Published: (2014)

Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial
by: Mandala, Justin, et al.
Published: (2014)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
by: Suzuki, Fumitaka, et al.
Published: (2014)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Jung, Sang Kyung, et al.
Published: (2015)

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years
by: Buti, Maria, et al.
Published: (2015)

Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure
by: Jose, Sophie, et al.
Published: (2014)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
by: Llibre, Josep M., et al.
Published: (2016)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
by: M. Llibre, Josep, et al.
Published: (2016)

Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
by: Avihingsanon, Anchalee, et al.
Published: (2012)